A functional drug re-purposing screening identifies carfilzomib as a drug preventing 17β-estradiol: ERα signaling and cell proliferation in breast cancer cells-Reference-Cited by-同舟云学术

A functional drug re-purposing screening identifies carfilzomib as a drug preventing 17β-estradiol: ERα signaling and cell proliferation in breast cancer cells

Published:2018-01 Issue: Volume:460 Page:229-237
ISSN:0303-7207
Container-title:Molecular and Cellular Endocrinology
language:en
Short-container-title:Molecular and Cellular Endocrinology

Author:

Busonero Claudia,Leone Stefano,Klemm Cinzia,Acconcia Filippo^ORCID

Funder

AIRC-Associazione Italiana Ricerca sul Cancro

Publisher

Elsevier BV

Subject

Endocrinology,Molecular Biology,Biochemistry

Reference47 articles.

1. The effects of 17beta-estradiol in cancer are mediated by estrogen receptor signaling at the plasma membrane;Acconcia;Front. Physiol.,2011

2. Xenoestrogen regulation of ERalpha/ERbeta balance in hormone-associated cancers;Acconcia;Mol. Cell Endocrinol.,2016

3. ESR1 mutations: moving towards guiding treatment decision-making in metastatic breast cancer patients;Angus;Cancer Treat. Rev.,2017

4. Structure-function relationship of estrogen receptor alpha and beta: impact on human health;Ascenzi;Mol. Asp. Med.,2006

5. Reference profile correlation reveals estrogen-like trancriptional activity of Curcumin;Bachmeier;Cell Physiol. Biochem.,2010

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug repurposing: a retrospective revolution in breast cancer medicine;Discover Medicine;2024-07-12

2. Selective impact of ALK and MELK inhibition on ERα stability and cell proliferation in cell lines representing distinct molecular phenotypes of breast cancer;Scientific Reports;2024-04-08

3. PMM2 controls ERα levels and cell proliferation in ESR1 Y537S variant expressing breast cancer cells;Molecular and Cellular Endocrinology;2024-04

4. Selective Impact of ALK and MELK Inhibition on ERα Stability and Cell Proliferation in Cell Lines Representing Distinct Molecular Phenotypes of Breast Cancer;2023-12-19

5. Proteasome inhibitors as anticancer agents;Expert Opinion on Therapeutic Patents;2023-10-30